Updates and news related to prostate cancer:
Radiopharmaceutical boosts survival
The authors stated that testosterone levels were high with late injections regardless of which therapy was used.
Patients who underwent advanced molecular imaging had higher rates of disease-free survival, according to new research.
Late adverse events indicate need for extended follow-up.
Prostate Radiation Therapy Tied to Improved Survival in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
An article from Us TOO International's newsletter
Patients with nonmetastatic castration-resistant prostate cancer continued to tolerate long-term treatment with Nubeqa.
Selecting Between Antiandrogen Agents in Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Natasha Garg, DO, medical oncologist, hematologist, and assistant clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, briefly discusses considerations.
18F-Fluciclovine-PET/CT Plus Conventional Imaging Improves Survival With Radiotherapy in Prostate Cancer
The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with...
FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U.S. by year end
A patient offers advice on getting patient portals, electronic medical records and technology organized and functioning correctly.